Bayban’s Emergent Biosolutions EBS Stock Holding History

Bayban’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56	Closed	-$465	–	613
2026 Q1	$465	Buy	+56	New	+$580	﹤0.01%	653

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

OHA

Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Bayban's EBS Position: Q2 2026 in Review

Bayban sold out of Emergent Biosolutions (EBS) in Q2 2026, closing a stake of 56 shares — an estimated $465 sold.

Bayban first reported a position in EBS in Q1 2026 and held it in 1 quarter. The position peaked at $465 in Q1 2026. 180 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

Bayban reported no remaining Emergent Biosolutions position as of Q2 2026 after selling out during the quarter.
Bayban sold 56 Emergent Biosolutions shares in Q2 2026, an estimated $465.
Bayban first reported a position in Emergent Biosolutions in Q1 2026 and held it in 1 quarter.
Bayban's Emergent Biosolutions position peaked at $465 in Q1 2026.
180 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Bayban's 13F filing for Q2 2026, filed 30 Jul 2026.